TrialBMJ open2020

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.

Helmut Butzkueven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.